Autosomal dominant polycystic kidney disease is a challenging disorder to diagnose and treat effectively. Promising research over the past decade has, however, provided novel interventions, modifications to clinical practice and new areas to investigate with the aim of identifying approaches to slow disease progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lantinga-van Leeuwen, I. S. et al. Lowering of Pkd1 is sufficient to cause polycystic kidney disease. Hum. Mol. Genet. 13, 3069–3077 (2004).
Cadnapaphornchai, M. A. et al. Prospective change in renal volume and function in children with ADPKD. Clin. J. Am. Soc. Nephrol. 4, 820–829 (2009).
Gile, R. D. et al. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am. J. Kidney Dis. 26, 501–507 (1995).
Cadnapaphornchai, M. et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 9, 889–896 (2014).
Schrier, R. W. et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J. Am. Soc. Nephrol. 13, 1733–1739 (2002).
Cadnapaphornchai, M. et al. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease. Kidney Int. 74, 1192–1196 (2008).
Schrier, R. W. et al. Blood pressure in early autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2255–2266 (2014).
Schrier, R. W. et al. Repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 22, 2361–2375 (2013).
Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
Kurbegovic, A. & Trudel, M. Progressive development of polycystic kidney disease in the mouse model expressing Pkd1 extracellular domain. Hum. Mol. Genet. 22, 2361–2375 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Schrier, R. Slowing progression of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 11, 638–639 (2015). https://doi.org/10.1038/nrneph.2015.164
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.164
This article is cited by
-
The effects of the renin–angiotensin–aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease
Irish Journal of Medical Science (1971 -) (2022)